Additionally, these results may support the further treatment selection strategy targeting IL-17A, TNFα, or other Th17-related cytokines, ultimately improving the management of rheumatic diseases by identifying the biologically rational treatment or combination for the patients. Here, IL17A is linked to rheumatic disorder.